Optimization of the dental implant with the use of ILIB: major considerations

Introduction: In the context of implantology and osseointegration for the stabilization of dental implants, the use of ILIB (Intravascular Laser Irradiation of Blood) to stimulate tissues, cells, and molecules at the systemic level stands out. In this sense, ILIB can be used with postoperative applications in the osseointegration and stability of dental implants. Objective: Conducted a concise systematic review of the main findings of using the ILIB to improve dental implant practices. Methods: The research was carried out from May 2021 to June 2021 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar, following the Systematic Review-PRISMA rules. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results: A total of 58 studies were analyzed, with only 10 medium and high-quality studies selected, according to GRADE rules, and with risks of bias that do not compromise scientific development. After analyzing the major studies, it was analyzed that, with the use of ILIB, several bone regeneration factors can be promoted and optimized for implant dentistry. Other authors have shown that ILIB therapy has oral sterilization properties, facilitating tissue healing after surgical procedures and the osseointegration process for placement of stable implants. Despite this, low-intensity laser irradiation may have limitations, as it requires specific dosimetry and few published studies on the use of ILIB in Dentistry. Conclusion: Literary findings point to the safety and efficacy of ILIB in dental implant treatments. The ILIB power is included as an eligibility criterion equal to other low power lasers. Furthermore, ILIB enables local and systemic treatment, optimizing the benefits of its use by dentists, mainly to improve the stabilization of osseointegrated implants and prevent or eliminate contamination

State of the art of blue light effects on hidradenitis suppurativa: a concise systematic review

Introduction: In the setting of inflammatory diseases, hidradenitis suppurativa (HS), or acne inversa, is an immune-mediated skin disease with a prevalence of 0.1-1% and characterized by nodules and abscesses in the armpits, groin, and inframammary areas, which may evolve for fistulas and scars. Still, an update is needed on the recent understanding of the pathogenesis of HS, including the central role of inflammatory cytokines and other contributing factors such as genetics, hormones, and pathogenic microorganisms. As an innovative approach, antimicrobial blue light in the 400-470 nm spectrum has demonstrated its intrinsic antimicrobial properties resulting from the presence of endogenous photosensitizing chromophores in pathogenic microorganisms. Objective: To carry out a narrative and systematic review of the literature to explore the main clinical and experimental results of the use of photobiomodulation with blue light for the treatment of hidradenitis suppurativa by antibacterial action. Methods: The present study followed a model of narrative and systematic review, according to PRISMA rules, to gather the main information about the efficiency and safety of blue light in the treatment of HS. The research was carried out from January 2018 to May 2019 and developed based on Google Scholar, Scopus, PubMed, Scielo, and Cochrane Library. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results: Microorganisms are less able to develop resistance to antimicrobial blue light than to traditional antibiotics, due to the multi-targeting characteristics of antimicrobial blue light. Furthermore, it is well accepted that antimicrobial blue light is much less harmful to host cells than UV irradiation. Clinical studies have presented scientific evidence of treatment for HS with light-based therapy, showing efficacy and safety through articles published in quality journals in scientific evidence. A meta-analysis published in 2019, based on the quality of the evidence, showed that the most recommended treatments for HS include adalimumab and laser (blue light) therapy. For intense pulsed light with blue light, two RCTs reported improvements in HS-LASI scores and the Dermatology Quality of Life Index. Conclusion: The use of blue light for dermal treatments, particularly for HS, is finding an increasing role in dermatology. However, more robust and consistent studies are still needed to better demonstrate the antibacterial effects of blue light on HS